

Hospital outpatient department: Sample CMS-1450 (UB-04) claim form

The CMS-1450 (UB-04) form is used for billing prescribed medications such as ZUSDURI™ (mitomycin) for intravesical solution administered in a hospital outpatient department setting. Refer to the notes below when populating the fields, which contain essential information the plans require for reimbursement. You are required to code to the highest level of specificity. Contact the third-party payer if you have questions about their specific procedures.

See additional HCPCS codes listed to the left, which may be applicable depending on the health insurance plan.

FL 42

Enter the 4-digit revenue code that best describes the service provided, in accordance with hospital billing policy.

FL 43

Enter a detailed description of the drug for the payer. List the N4 indicator first and the 11-digit NDC number second. Third, add the unit of measurement qualifier, then the unit quantity at the end.

FL 44-46

Bill for ZUSDURI with the following HCPCS codes:
 C9399 – Unclassified drugs or biologicals
 J9999 – Not otherwise classified, antineoplastic drugs
 J3490* – Unclassified drugs
 J3590* – Unclassified biologics

To report the administration procedure, enter the appropriate CPT® code 51720 and corresponding service units.

FL 66

Enter the appropriate **ICD-10-CM diagnosis codes for bladder cancer, which may include:**

- C67 Malignant neoplasm of bladder
- C67.0 Malignant neoplasm of trigone of bladder
- C67.1 Malignant neoplasm of dome of bladder
- C67.2 Malignant neoplasm of lateral wall of bladder
- C67.3 Malignant neoplasm of anterior wall of bladder
- C67.4 Malignant neoplasm of posterior wall of bladder
- C67.5 Malignant neoplasm of bladder neck
- C67.6 Malignant neoplasm of ureteric orifice
- C67.7 Malignant neoplasm of urachus
- C67.8 Malignant neoplasm of overlapping sites of bladder
- C67.9 Malignant neoplasm of bladder, unspecified

FL 80

Enter the drug name, the quantity of drug administered, route of administration, and NDC in the remarks section as needed. This can be required by payers when billing an HCPCS code. When billing with a miscellaneous code, wastage is recorded here. For example, if a patient receives 75 mg from an 80-mg vial of medication, the 5 mg wastage is recoded as “ME5JW.”

43 REV. CD.	43 DESCRIPTION	44 ICD-10-CM / ICD-9-CM / HCPCS CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49
0636	N4 72493010603 ME 80	C9399	XX/XX/XX	1			1
0510	Bladder instillation anticarcinogen agent	51720	XX/XX/XX	1			2

50 REVER NAME		51 HEALTH PLAN ID		54 PRIOR PAYMENTS		55 EST. AMOUNT DUE		56 NPI	
58 INSURED'S NAME		59 PREL		60 INSURED'S UNIQUE ID		61 GROUP NAME		62 INSURANCE GROUP NO.	
63 TREATMENT AUTHORIZATION CODES		64 DOCUMENT CONTROL NUMBER		65 EMPLOYER NAME					
66 ADMIT DATE		67 PATIENT REASON DX		68 ICD-10-CM		69 ICD-9-CM		70 ICD-10-PCS	
71 PRINCIPAL PROCEDURE CODE		72 OTHER PROCEDURE CODE		73 OTHER PROCEDURE CODE		74 OTHER PROCEDURE CODE		75 ATTENDING NPI	
76 LAST		77 OPERATING NPI		78 OTHER NPI		79 OTHER NPI		80 OTHER NPI	
81 REMARKS		82 ICD-10-CM		83 ICD-9-CM		84 ICD-10-PCS		85 OTHER NPI	
72493010603 ZUSDURI									
instillation ME75 ME5JW									

*Code used where applicable.

CPT, Common Procedural Terminology; FL, Form Locator; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

Content is informational only and does not constitute medical, legal, or reimbursement advice and represents no statement, promise, or guarantee of payment. The provider is solely responsible for determining appropriate treatment for the patient based on the unique medical needs of each patient and the independent judgment of the provider. It is also the responsibility of the provider to determine payer-appropriate coding, medical necessity, site of service, documentation requirements, and payment levels and to submit appropriate codes, modifiers, and charges for services rendered. Although we have made every effort to provide information that is current at the time of its issue, it is recommended you consult your legal counsel, reimbursement/compliance advisor, and/or payer organization(s) for interpretation of payer-specific coding, coverage, and payment expectations.



UroGen® is a registered trademark and ZUSDURI™ and UroGen Support™ are trademarks of UroGen Pharma, Ltd. All other trademarks are the property of their respective owners. © 2025 UroGen Pharma, Inc. All rights reserved. US-UGN-00339 06/25

